TASLY(600535) 证券时报网·2024-10-27 10:06Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a slight increase in revenue for the first three quarters of the year, with a focus on steady growth in its modern traditional Chinese medicine segment and significant recovery in its chemical preparations segment [1] Group 1: Financial Performance - The pharmaceutical industrial revenue for the first three quarters reached 5.737 billion yuan, a year-on-year increase of 2.18% [1] - The modern traditional Chinese medicine segment generated 4.578 billion yuan, with a growth of 0.51% year-on-year [1] - The cardiovascular segment saw a year-on-year growth of 3.54%, with core products showing positive growth [1] - The chemical preparations segment achieved revenue of 966 million yuan, marking an 11.08% increase, driven by rapid growth in the sales of water-lin-jia and a recovery in anti-tumor product sales [1] Group 2: Dividend and R&D Investment - The company announced a cash dividend of 0.70 yuan per 10 shares (before tax), bringing the total cash dividend per share to 0.33 yuan for the first three quarters of the year [1] - Research and development investment for the first three quarters amounted to 565 million yuan, showing a slight increase compared to the same period last year [1] Group 3: R&D Pipeline - The company has a pipeline of 25 products in modern traditional Chinese medicine research [1] - Two products, Pi Pa Qing Fei Yin and Wen Jing Tang, are in the production application stage, having passed drug registration and production site inspections [1] - Nineteen products are in clinical phases II and III, with several projects, including An Shen Di Wan and Qing Zhu Ke Li, having entered clinical phase III [1] - The company’s significant biopharmaceutical product, Pu You Ke, has expanded its indications from treating acute ST-segment elevation myocardial infarction to acute ischemic stroke, with the latest phase IIIc validation trial report submitted for production application [1]